
Hematology Clinic
The Pediatric Hematology Clinic provides comprehensive care for children and adolescents who have noncancerous blood conditions, including anemias; abnormalities of red or white blood cells and platelets; and inherited disorders, such as sickle cell disease and hemophilia. For blood cancer care, please see our Pediatric Cancer Program.
Depending on the disease, our clinic offers treatments ranging from medications and immunotherapies to complex transfusions and bone marrow transplants. Being based at a hospital that's active in research on blood disorders, we're able to access new treatments as soon as they're proven safe and effective.
We understand that the diagnosis and treatment of a blood disorder can be difficult for young patients, both physically and emotionally. For that reason, we're dedicated to giving our patients not only the highest quality medical care but also to offering a range of support services to make the journey smoother.
Our team includes doctors who are experts in pediatric blood diseases as well as nurse specialists, psychologists, social workers and child life specialists. When a patient is eligible for a transplant, we collaborate with the Pediatric Blood & Marrow Transplant Clinic. Our goals are to ensure the best possible outcomes and offer every child an improved and lasting quality of life.
Our locations (7)
Our team
-
Shreya Agarwal
MD
Pediatric hematologist -
Neha Bhasin
MD
Pediatric hematologist-oncologist -
Maria I. Castellanos
MD
Pediatric hematologist-oncologist -
Robert Ward Hagar
MD, JD
Internist -
Caroline Hastings
MD
Hematologist-oncologist and neuro-oncologist -
Michelle L. Hermiston
MD, PhD
Pediatric hematologist-oncologist -
James Huang
MD
Pediatric hematologist -
Ashutosh Lal
MD, MBBS
Pediatric hematologist-oncologist -
Nahal Lalefar
MD
Pediatric hematologist-oncologist -
Alison Matsunaga
MD
Pediatric hematologist-oncologist -
Jennifer Michlitsch
MD
Pediatric hematologist-oncologist -
Elizabeth Robbins
MD
Pediatric hematologist-oncologist -
Kristin A. Shimano
MD
Pediatric hematologist-oncologist -
Sylvia Singer
MD
Pediatric hematologist-oncologist -
Elliott Vichinsky
MD
Pediatric hematologist-oncologist -
Madhav Vissa
MD
Pediatric hematologist-oncologist -
Beth Apsel Winger
MD, PhD
Pediatric hematologist-oncologist -
Mary B. Lesh
NP
Pediatric nurse practitioner -
Laura Quill
CPNP
Pediatric nurse practitioner -
Katrina Unpingco
FNP
Nurse practitioner
Awards & recognition
-
Ranked among the nation's best in 11 specialties
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your child's condition
- List of medications, including dosages, plus any your child is allergic to
- List of questions you may have
- Device or paper for taking notes
- Completed medical forms that we will mail to you ahead of time
Related clinics (8)

Blood & Marrow Transplant (BMT) Clinic
Support services
Clinical trials
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
To compare the rate of MRD >=0.01% at end of induction between experimental arm and control arm
Recruiting
More about this studyProject: Every Child for Younger Patients With Cancer
The number of patients who agree to be in the Biobanking part of the study and have leftover tumor tissue and some normal blood, bone marrow, or other tissue saved for future research.
Recruiting
More about this studyChemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusi...
The Kaplan-Meier method will be used to estimate 3-year FFS along with 80% log-minus-log transformed confidence limits for very low risk (VLR) patients.
Recruiting
More about this studyInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...
Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...
Recruiting
More about this studyDinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Child...
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.
Recruiting
More about this studyA Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Seve...
The median time to failure or death will be compared on the two arms using the log-rank test. Failure of IST is defined as the date that a second definitive therapy was recommended (BMT, second course of ATG) and failure of BMT de...
Recruiting
More about this studyCobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Proportion of participants with (complete response, partial response, stable disease, progressive disease) by 1 year of therapy with Cobimetinib. It is assumed that at each protocol-specified timepoint, a response assessment occu...
Recruiting
More about this studyA Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Seve...
The median time to failure or death will be compared on the two arms using the log-rank test. Failure of IST is defined as the date that a second definitive therapy was recommended (BMT, second course of ATG) and failure of BMT de...
Recruiting
More about this studyA Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute ...
Summary statistics will be used to characterize the study populations on CHC outcomes. Quantitative data (number of comorbidities) will be summarized using descriptive statistics and correlational techniques. Will use pooled logis...
Recruiting
More about this studyThe Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in...
The proportion will be calculated as the percent of eligible patients who are identified to have an a priori specified genomic or immunophenotypic target and who enroll on at least one of the sub-trials. The corresponding confiden...
Recruiting
More about this studyOur research initiatives
Saving future lives
500+ UCSF investigators are researching cures for hundreds of childhood and adult diseases.
